179 related articles for article (PubMed ID: 27485071)
1. Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy.
Temme A; Schmitz M
Immunotherapy; 2016 Sep; 8(9):983-6. PubMed ID: 27485071
[No Abstract] [Full Text] [Related]
2. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.
Bollino D; Webb TJ
Transl Res; 2017 Sep; 187():32-43. PubMed ID: 28651074
[TBL] [Abstract][Full Text] [Related]
4. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
5. Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.
Siegler EL; Kim YJ; Chen X; Siriwon N; Mac J; Rohrs JA; Bryson PD; Wang P
Mol Ther; 2017 Dec; 25(12):2607-2619. PubMed ID: 28919377
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
7. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
Chmielewski M; Kopecky C; Hombach AA; Abken H
Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
[TBL] [Abstract][Full Text] [Related]
8. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Zhuang X; Long EO
Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells in cancer.
Höglund P; Klein E
Semin Cancer Biol; 2006 Oct; 16(5):331-2. PubMed ID: 16931040
[No Abstract] [Full Text] [Related]
10. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
Lin C; Zhang J
Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
[TBL] [Abstract][Full Text] [Related]
11. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
12. Application of Genome Editing Techniques in Immunology.
Zych AO; Bajor M; Zagozdzon R
Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):289-298. PubMed ID: 29344676
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
14. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptors (CARs) from bench-to-bedside.
Savoldo B; Dotti G
Immunol Lett; 2013; 155(1-2):40-2. PubMed ID: 24080488
[TBL] [Abstract][Full Text] [Related]
16. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
Mantesso S; Geerts D; Spanholtz J; Kučerová L
Front Immunol; 2020; 11():607131. PubMed ID: 33391277
[TBL] [Abstract][Full Text] [Related]
17. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell immunotherapy for cancer: a new hope.
Srivastava S; Lundqvist A; Childs RW
Cytotherapy; 2008; 10(8):775-83. PubMed ID: 19089686
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell lines in tumor immunotherapy.
Cheng M; Zhang J; Jiang W; Chen Y; Tian Z
Front Med; 2012 Mar; 6(1):56-66. PubMed ID: 22460449
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
